Last updated 2 days ago
A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)
278 patients around the world
Available in Spain, Brazil, Argentina, United States, Mexico
Bayer
16Research sites
278Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
25 de mayo 174, Viedma, Río Negrowww.imoviedma.com.ar
Av. Galvan 4102, CABA, Buenos Aireswww.cemic.edu.ar/
Monseñor Pablo Cabrera 2941, Córdobawww.cemaic.com.ar
Juan Domingo Perón 4190, Piso 1, Ciudad Autónoma de Buenos Aires, C1181ACH
Rua Professor Annes Dias - Centro Histórico, Porto Alegre - RS, 90020-090, Brazil
R. Dr. Albuquerque Lins, 40 - Santa Cecilia, São Paulo - SP, 01230-001, Brazil
Rua Antenor Duarte Villela 1331 - Barretos, Sao Paulo, 14784-400
Avenida Brigadeiro Faria Lima, 4300 - Vila Olímpia, São Paulo - SP, 04538, Brazil
Natal, Rio Grande Do Norte, 59075-740
Viad. Río Becerra 27, Nápoles, Benito Juárez, 03810 Ciudad de México
StudySOHO-02
SponsorBayer
Conditions
Non-small cell lung carcinoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06452277
